الفهرس 
Classification of Myeloproliferative NeoplasmsOnly 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
Progress in the treatment of cancer and leukemia requires an ever increasing committment and diligence in monitoring the response to treatment,minimal residual disease, and the course of the disease. For CML, blood counts and differential were sufficient until the introduction of interferon and allogeneic stem cell transplantation, which began to require cytogenetic and molecular monitoring.With the introduction of tyrosine kinase inhibitors, both quantitative and qualitative cytogenetic and molecular monitoring has become mandatory in all patients, and drug plasma level assays will very soon become necessary. This may have an impact on costs. Performing three cytogenetic tests and four RQPCR per year may cost between 1250 and 1600 euro per year, corresponding to a small fraction of the cost of the drug, from a minimum of 2.5% (assuming 1250 euro for the tests, and 50,000 euro for the drug) to a maximun of 6.4% (assuming 1600 eura for the tests and 25,000 euro for the drug).